| Drug ID: | Drug173 |
|---|---|
| Drug Name: | Deucravacitinib |
| CID: | 134821691 |
| DrugBank ID: | DB16650 |
| Modality: | Small Molecule |
| Groups: | NULL |
| US Approved: | YES |
| Other Approved: | YES |
| Identifier: | NCT03934216, , NCT04613518, , NCT03599622, , NCT03262727, , NCT03254784, , NCT04877990 |
| Molecular Formula: | C20H22N8O3 |
| Molecular Weight: | 425.5 g/mol |
| Isomeric SMILES: | [2H]C([2H])([2H])NC(=O)C1=NN=C(C=C1NC2=CC=CC(=C2OC)C3=NN(C=N3)C)NC(=O)C4CC4 |
| Synonyms: | Deucravacitinib; 1609392-27-9; BMS-986165; Tyk2-IN-4; Sotyktu; BMS986165; N0A21N6RAU; UNII-N0A21N6RAU; compound 11 (PMID: 31318208); compound 11 [PMID: 31318208} |
| Phase 0: | 2 |
| Phase 1: | 35 |
| Phase 2: | 20 |
| Phase 3: | 17 |
| Phase 4: | 9 |
| Description: | NULL |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt1258 | 134821691 | Deucravacitinib | 2047 | EPHB1 | Homo sapiens (human) | Modulator | |
| dt1259 | 134821691 | Deucravacitinib | 7297 | TYK2 | Homo sapiens (human) | Inhibitor | |
| dt1260 | 134821691 | Deucravacitinib | 1794 | DOCK2 | Homo sapiens (human) | Inhibitor | |
| dt1261 | 134821691 | Deucravacitinib | 7297 | TYK2 | Homo sapiens (human) | Modulator | |
| dt1262 | 134821691 | Deucravacitinib | 659 | BMPR2 | Homo sapiens (human) | 31318208 | Inhibition |
| dt1263 | 134821691 | Deucravacitinib | 7297 | TYK2 | Homo sapiens (human) | Tyrosine-protein kinase TYK2 negative allosteric modulator | |
| dt1264 | 134821691 | Deucravacitinib | 3716 | JAK1 | Homo sapiens (human) | 31318208 | Inhibition |
| dt1265 | 134821691 | Deucravacitinib | 7297 | TYK2 | Homo sapiens (human) | 31318208 | Inhibition |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT04877990 | A Study to Evaluate the Long-term Safety and Efficacy of Deucravacitinib in Participants With Crohn's Disease or Ulcerative Colitis | PHASE2 | COMPLETED | Bristol-Myers Squibb | Crohn Disease|Ulcerative Colitis | DRUG: Deucravacitinib | Details |
| NCT03934216 | Safety and Efficacy of Deucravacitinib in Participants With Moderate to Severe Ulcerative Colitis | PHASE2 | COMPLETED | Bristol-Myers Squibb | Ulcerative Colitis | DRUG: BMS-986165|OTHER: Placebo | Details |
| NCT04613518 | A Study of the Safety, Efficacy, and Biomarker Response of BMS-986165 in Participants With Moderate to Severe Ulcerative Colitis | PHASE2 | COMPLETED | Bristol-Myers Squibb | Colitis, Ulcerative | DRUG: BMS-986165|OTHER: Placebo Comparator | Details |
| NCT03599622 | An Investigational Study of Experimental Medication BMS-986165 in Participants With Moderate to Severe Crohn's Disease | PHASE2 | TERMINATED | Bristol-Myers Squibb | Granulomatous Colitis|Crohn's Disease|Crohn's Ent… | DRUG: BMS-986165|OTHER: Placebo | Details |
| NCT03262727 | The Effect of BMS-986165 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Patients | PHASE1 | COMPLETED | Bristol-Myers Squibb | Systemic Lupus Erythematosus; Arthritic Psoriasis… | DRUG: BMS-986165; DRUG: Loestrin 1.5/30 (1.5 mg n… | Details |
| NCT03254784 | A Study to Evaluate BMS-986165 Tablet Formulation Relative to BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal and Increased Gastric pH on the BMS-986165 Tablet Formulation | PHASE1 | COMPLETED | Bristol-Myers Squibb | Systemic Lupus Erythematosus; Arthritic Psoriasis… | DRUG: BMS-986165 Capsule; DRUG: BMS-986165 Tablet | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| No data available | |||||
Deucravacitinib: First Approval
PMID: 36401743
Year: 2022
Relationship Type:
Treatment
Score: 7.5
Deucravacitinib (SOTYKTU) is a first-in-class, highly selective, oral tyrosine kinase 2 (TYK2) inhibitor. It acts via an allosteric mechanism, bindin…
Deucravacitinib in patients with inflammatory bowel disease: 12-week efficacy a…
PMID: 40355364
Year: 2025
Relationship Type:
Treatment
Score: 6.5
BACKGROUND AND AIMS: Tyrosine kinase 2 is a downstream intracellular mediator of interleukin-23 signaling, which has a key role in the pathogenesis o…
The Expanding Therapeutic Potential of Deucravacitinib Beyond Psoriasis: A Narr…
PMID: 40095888
Year: 2025
Relationship Type:
Treatment
Score: 6.5
Deucravacitinib is an allosteric, selective tyrosine kinase 2 (TYK2) inhibitor that has demonstrated significant efficacy in the treatment of psorias…